Peripheral and dual binding site inhibitors of acetylcholinesterase as neurodegenerative disease modifying agents

Bibliography

• LEIFER BP: Early diagnosis of Alzheimer's disease: clinical and economic benefits. J. Am. Ceriatr. Soc. (2003) 51:281–288.
   Google Scholar
• KNOPMAN D: Pharmacotherapy for Alzheimer's disease. Clin. Neuropharmacol (2003) 26:93–101.
   PubMed Web of Science ®Google Scholar
• DEKOSKY ST: Pathology and pathways of Alzheimer's disease with an update on new developments in treatment. J. Am. Ceriatr. Soc. (2003) 51:314–320.
   Google Scholar
• LAHIRI DK, FARLOW MR, SAMBAMURTI K, GREIG NH, GIACOBINI E, SCHNEIDER LS: A critical analysis of new molecular targets and strategies for drug developments in Alzheimer's disease. Cum Drug Targets (2003) 4:97–112.
   PubMed Web of Science ®Google Scholar
• •A comprehensive review of new drugs under research for future AD treatments.
   Google Scholar
• TARIOT PN, FEDEROFF HJ: Current treatment for Alzheimer's disease and future prospects. Alzheimer Dis. Assoc. Disord. (2003) 17:105–113.
   PubMed Web of Science ®Google Scholar
• KURZ A: The therapeutical potential of tacrine. Neural. Transm. Sapp]. (1998) 54:295–299.
   PubMedGoogle Scholar
• SUGIMOTO H: Donepezilhydrochloride: a treatment drug for Alzheimer's disease. Chem. Rec. (2001) 1:63–73.
   Google Scholar
• JANN MW: Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease. Pharmacotherapy (2000) 20:1–12.
   PubMedGoogle Scholar
• ZAROTSKY V, SRAMEK JJ, CUTLER NR: Galantamine hydrobromide: an agent for Alzheimer's disease. Am. J. Health Syst. Pharm. (2003) 60:446–452.
   PubMed Web of Science ®Google Scholar
• MINTZER JE, KERSHAW P: The efficacy of galantamine in the treatment of Alzheimer's disease: comparison of patients previously treated with acetylcholinesterase inhibitors to patients with no prior exposure. Int. J. Ceriatr. Psychiatry (2003) 18:292–297.
   PubMed Web of Science ®Google Scholar
• COREY-BLOOM J: Galantamine: a review of its use in Alzheimer's disease and vascular dementia. Int. j Clin. Pract. (2003) 57:219–223.
   PubMed Web of Science ®Google Scholar
• SAMOCHOCKI M, HOFFLE A, FEHRENBACHER A et al.: Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. Pharmacol Exp. Ther. (2003) 305:1024–1036.
   PubMed Web of Science ®Google Scholar
• GEERTS H, FINKEL L, CARR R, SPIROS A: Nicotinic receptor modulation: advantages for successful Alzheimer's disease therapy. I Neural. Bansm. Stipp] (2002) 62:203–216.
   PubMedGoogle Scholar
• WOODRUFF-PAK DS, LANDER C, GEERTS H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. (2002) 8:405–426.
   PubMedGoogle Scholar
• GIACOBINI E: Cholinesterases: new rolesin brain function and in Alzheimer's disease. Neurochem. Res. (2003) 28:515–522.
   Google Scholar
• •The efficacy of cholinesterase inhibitor treatment in clinical trials is reported.
   Google Scholar
• LANCTOT KL, HERRMAN N, LOULOU MM: Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease. Psychiatry Neurosci. (2003) 28:13–26.
   PubMed Web of Science ®Google Scholar
• SOREQ H, SEIDMAN S: Acetylcholinesterase: new roles for an old actor. Nat. Rev Neurosci. (2001) 2:294–302.
   PubMed Web of Science ®Google Scholar
• MUISIOZ FJ, ALDUNATE R, INESTROSA NC: Peripheral binding site is involved in the neurotrophic activity of acetylcholinesterase. Neumreport (1999) 26:3621–3625.
   Google Scholar
• BLASINA MF, FARIA AC, GARDINO PFet al.: Evidence of non-cholinergic function of acetylcholinesterase during development of chicken retina as shown by fasciculin. Cell Tissue Res. (2000) 299:173–184.
   Google Scholar
• PAKASKI M, KASA P: Role of acetylcholinesterase inhibitors in the metabolism of amyloid precursor protein. Cuir. Drug Target CNS Neurol Disord. (2003) 2:163–171.
   PubMedGoogle Scholar
• PAKASKI M, RAKONCZAY Z, KASA P: Reversible and irreversible acetylcholinesterase inhibitors cause changes in neuronal amyloid precursor protein processing and protein kinase C level in vitro. Neurochem. Int. (2001) 38:219–226
   PubMed Web of Science ®Google Scholar
• ALVAREZ A, OPAZO C, ALARCON R, GARRIDO J, INESTROSA NC: Acetylcholinesterase promotes the aggregation of amyloid-3-peptide fragments by forming a complex with the growing fibrils. Ma Biol. (1997) 272:348–361.
   Google Scholar
• SHARMA KV, KOENIGSBERGER C, BRIMIJOIN S, BIGBEE JW: Direct evidence for an adhesive function in the non-cholinergic role of acetylcholinesterase in neurite outgrowth. I Neurosci. Res. (2001) 63:165–175.
   Google Scholar
• JOHNSON G, MOORE SW: The adhesion function on acetylcholinesterase is located at the peripheral anion site. Biochem. Biophys. Res. Commun. (1999) 258:758–762.
   PubMed Web of Science ®Google Scholar
• AULD DS, KORNECOOK TJ, BASTIANETTO S, QUIRON R: Alzheimer's disease and the basal forebrain cholinergic system: relations to 3-amyloid peptides, cognition and treatment strategies. Frog. Neurobiol (2002) 68:209–245.
   Google Scholar
• INESTROSA NC, ALARCON R: Molecular interactions of acetylcholinesterase with senile plaques. J. Physic] Paris (1998) 92:341–344.
   PubMed Web of Science ®Google Scholar
• CAMPOS EO, ALVAREZ A, INESTROSA NC: Brain acetylcholinestersae promotes amyloid-3-peptide aggregation but does not hydrolize amyloid precursor protein peptides. Neurochem. Res. (1998) 23:135–140.
   PubMed Web of Science ®Google Scholar
• INESTROSA NC, ALVAREZ A, CALDERON F: Acetylcholinesterase is a senile plaque component that promotes assembly of amyloid 3-peptide into Alzheimer's filaments. Ma Psychiatry (1996) 1:359–361.
   Google Scholar
• HU W, GRAY NW, BRIMIJOIN S: Amyloid-I3 increases acetylcholinestersae expression in neuroblastoma cells by reducing enzyme degradation. Neurochem. (2003) 86:470–478.
   PubMedGoogle Scholar
• SAEZ-VALERO J, FODERO LR, WHITE AR, BARROW CJ, SMALL DH: Acetylcholinestersae is increased in mouse neuronal and astrocyte cultures after treatment with 3-amyloid peptides. Brant Res. (2003) 965:283–286.
   Google Scholar
• PANG YP, QUIRAM E JELACIC T, HONG F, BRIMIJOIN S: Highly potent, selective, and low-cost bis-tetrahydroaminoacrine inhibitors of acetylcholinesterase. Biol. Chem. (1996) 271:23646–23649.
   Google Scholar
• KOELLNER G, KRIGER G, MILLARD CB, SILMAN I, SUSSMAN JL, STEINER T: Active-site gorge and buried water molecules in crystal structures of acetylcholinesterase from Torpedo californica.Biol (2000)296:713–735.
   Google Scholar
• SCHALK I, EHRET-SABATIER L, BOUET F, GOELDNER M, HIRTH C: T93219 is involved in the binding of quaternary ammonium at the peripheral site of Torpedo californica acetylcholinesterase. Eur. Biochem. (1994) 219:155–159.
   PubMedGoogle Scholar
• CASTRO A, MARTINEZ A: Peripheral and dual binding site acetylcholinesterase inhibitors: implications in the treatment of Alzheimer's disease. Mini Rev Med. Chem. (2001) 1:267–272.
   PubMed Web of Science ®Google Scholar
• •Review of dual binding site AChEIs.
   Google Scholar
• REES TM, BRIMIJOIN S: The role of acetylcholinesterase in the pathogenesis of Alzheimer's disease. Drugs Today(2003) 39:75–83.
   PubMed Web of Science ®Google Scholar
• •Interesting manuscript in which relationships between AChE, B-arnyloid and their involvement in AD pathogenesis is clearly discussed.
   Google Scholar
• CASTRO A, RICHARDS WG, LYNE P: The design of novel acetylcholinesterase inhibitors using the multiple copy simultaneous search method. Med. Chem. Res. (1999) 9:98–107.
   Web of Science ®Google Scholar
• CASTRO A, HERNANDEZ L, DORRONSORO I et al.: Synthesis, biological evalution and modelling studies of dual binding acetylcholinesterase inhibitors. Med. Res. Chem. (in press).
   Google Scholar
• BARTOLINI M, BERTUCCI C, CAVRINI V, ANDRISANO V: P-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. Biochem. Pharmacol. (2003) 65:407–416.
   PubMed Web of Science ®Google Scholar
• •Very detailed manuscript with a complete biological method for testing the anti-B-arnyloid aggregation of AChEIs
   Google Scholar
• MELCHIORRE C, ANTONELLO A, BANZI R et al: Polymethylene tetramine backbone as template for the development of biologically active polyamines. Med. Res. Rev (2003) 23:200–233.
   Google Scholar
• PANG YP, KOLLMEYER TM, HONG F et al.: Rational design of alkylene-linked bis-pyridiniumaldwdmes as improved acetylcholinesterase reactivators. Chem. Biol. (2003) 10:491–502.
   PubMed Web of Science ®Google Scholar
• LUTTMANN E, LINNEMANN E, FELS G: Galantamine as his-functional ligand for the acetylcholinesterase. Mol. Model (2002) 8:208–216.
   PubMed Web of Science ®Google Scholar
• PIAZZI L, RAMPA A, BISI A et al.: 3-(4-Benzyl(methyl)amino]methyllpheny1)-6,7-dimethoxy 2H 2 chromenone (AP-2238) inhibits both acetylcholinesterase and acetylcholinesterase-induced P-amyloid aggregation: a dual function lead for Alzheimer's disease therapy. j Med. Chem. (2003) 46:2279–2282.
   PubMed Web of Science ®Google Scholar
• ••Review of the first molecule described thattargets B-arnyloid aggregation through AChE inhibition.
   Google Scholar
• WINDISH M, HUTTER-PAIER B, SCHREINER E: Current drugs and future hopes in the treatment of Alzheimer's disease.' Neural. Tansm. Sapp]. (2002) 62:149–164.
   Google Scholar
• RECANATINI M, CAVALLI A: Acetylcholinesterase inhibitors in the context of therapeutic strategies to combat Alzheimer's disease. Expert Opin. Ther. Pat. (2002) 12:1853–1865.
   Web of Science ®Google Scholar
• ••A complete recent patent revision onAChEIs. Absolutely complementary to the present review.
   Google Scholar
• NICOLET Y, LOCKRIDGE O, MASS ON P, FONTECILLA- CAMPSJC, NACHON F: Crystal structure of human butyryl cholinestersae and of its complexes with substrates and products." Biol. Chem. (2003) [Epub ahead of print].
   Google Scholar
• REES T, HAMMOND PI, SOREQ H, YOUNKIN S, BRIMIJOIN S: Acetylcholinesterase promotes P-amyloid plaques in cerebral cortex. Neurobiol. Aging (2003) 24(0777–787.
   PubMed Web of Science ®Google Scholar